Your session is about to expire
← Back to Search
DVX201 for Coronavirus Pneumonia
Study Summary
This trial is testing an NK cell therapy to see if it can help people with COVID-19. NK cells are a part of the immune system that can kill cells infected by viruses. This study will look at the safety and tolerability of the therapy in patients with COVID-19.
- Coronavirus Pneumonia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What degree of risk do participants face while using DVX201?
"The limited information present in the Phase 1 trial of DVX201 earned it a score of 1 for safety."
Are there current opportunities for patients to participate in this research?
"Affirmative. According to clinicaltrials.gov, this research study is currently in the process of recruiting participants and was initially introduced on August 2nd 2021. The last update to the trial occurred on February 11th 2022; 18 individuals must be enrolled at a single location."
Are elderly individuals being considered for enrollment into this clinical trial?
"This experiment has an age cutoff of 80 years. All participants must be over 18 to participate."
How extensive is the pool of participants for this clinical trial?
"Affirmative. The clinicaltrials.gov record states that this trial is seeking additional participants, having first been listed on August 2nd 2021 and most recently updated February 11th 2022. 18 volunteers are needed from a single medical centre."
Who can participate in this medical research experiment?
"This medical experiment seeks 18 volunteers aged between 18 and 80 who have been infected with covid-19. Essential qualifications include having experienced the onset of symptoms within a week after consenting to participate, exhibiting a SpO2 level above 93% at rest (with supplemental oxygen – up to 4L by low flow O2 delivery - permitted but not essential), and if of reproductive age, agreeing to use an efficient form of contraception for 3 months following treatment."
Share this study with friends
Copy Link
Messenger